tiprankstipranks
Advertisement
Advertisement

DE:8F8 Stock Latest News

SynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
Company AnnouncementsSynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
9d ago
SynAct preclinical data point to osteoarthritis potential for resomelagon
PremiumCompany Announcements
SynAct preclinical data point to osteoarthritis potential for resomelagon
20d ago
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
PremiumCompany Announcements
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
30d ago
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
PremiumCompany Announcements
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
1M ago
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
PremiumCompany Announcements
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
1M ago
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
PremiumCompany AnnouncementsSynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
2M ago
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
Premium
Company Announcements
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
2M ago
8F8
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
Premium
Company Announcements
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
2M ago
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
PremiumCompany Announcements
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
2M ago
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
PremiumCompany Announcements
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
2M ago
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
PremiumCompany Announcements
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
2M ago
SynAct Pharma convenes AGM and opts to retain earnings
PremiumCompany Announcements
SynAct Pharma convenes AGM and opts to retain earnings
3M ago
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
PremiumCompany AnnouncementsSynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
3M ago
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
Premium
Company Announcements
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
3M ago
SynAct Pharma Updates Nomination Committee Ahead of 2026 AGM
Premium
Company Announcements
SynAct Pharma Updates Nomination Committee Ahead of 2026 AGM
3M ago
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
PremiumCompany Announcements
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
3M ago
SynAct Pharma Raises Share Capital Through Directed Issue
PremiumCompany Announcements
SynAct Pharma Raises Share Capital Through Directed Issue
4M ago
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
PremiumCompany Announcements
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
4M ago
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
PremiumCompany Announcements
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
4M ago
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
PremiumCompany AnnouncementsSynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
5M ago
SynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
Premium
Company Announcements
SynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
5M ago
SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
Premium
Company Announcements
SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >